#AI in clinical transfusion meets high-throughput genomic blood typing in this Precision Hematology webinar. Learn how antigen profiling and machine learning are improving blood allocation and transfusion outcomes.
Enroll: academy.hematology.o...
#HemeSky #MedSky
Enroll: academy.hematology.o...
#HemeSky #MedSky
February 19, 2026 at 1:00 PM
#AI in clinical transfusion meets high-throughput genomic blood typing in this Precision Hematology webinar. Learn how antigen profiling and machine learning are improving blood allocation and transfusion outcomes.
Enroll: academy.hematology.o...
#HemeSky #MedSky
Enroll: academy.hematology.o...
#HemeSky #MedSky
Postdoctoral Researcher in Clinical Genetics with a Focus on Molecular Hematology
Karolinska Institute - Sweden
Read the full job description and apply⤵️
jobrxiv.org/job/postdoct...
Karolinska Institute - Sweden
Read the full job description and apply⤵️
jobrxiv.org/job/postdoct...
February 19, 2026 at 6:26 AM
Postdoctoral Researcher in Clinical Genetics with a Focus on Molecular Hematology
Karolinska Institute - Sweden
Read the full job description and apply⤵️
jobrxiv.org/job/postdoct...
Karolinska Institute - Sweden
Read the full job description and apply⤵️
jobrxiv.org/job/postdoct...
It's possible that I told the PA at hematology that I wasn't doing that badly with fatigue from the standpoint of a person who has previously shocked ER doctors by being upright
February 19, 2026 at 5:39 AM
It's possible that I told the PA at hematology that I wasn't doing that badly with fatigue from the standpoint of a person who has previously shocked ER doctors by being upright
🧬Today’s question focuses on the biological basis of adverse effects seen with talquetamab therapy.
See the answer and explanation on the next slide!
#MultipleMyeloma #MedEd #Hematology #Talquetamab #BispecificAntibodies #ClinicalTrials #HemeOnc #Immunotherapy #HEMEHUB
See the answer and explanation on the next slide!
#MultipleMyeloma #MedEd #Hematology #Talquetamab #BispecificAntibodies #ClinicalTrials #HemeOnc #Immunotherapy #HEMEHUB
February 19, 2026 at 2:46 AM
🧬Today’s question focuses on the biological basis of adverse effects seen with talquetamab therapy.
See the answer and explanation on the next slide!
#MultipleMyeloma #MedEd #Hematology #Talquetamab #BispecificAntibodies #ClinicalTrials #HemeOnc #Immunotherapy #HEMEHUB
See the answer and explanation on the next slide!
#MultipleMyeloma #MedEd #Hematology #Talquetamab #BispecificAntibodies #ClinicalTrials #HemeOnc #Immunotherapy #HEMEHUB
🩸Facts about Multiple Myeloma:
Resistance and Biomarkers
#Hematology #MultipleMyeloma #MedEd #Immunotherapy #BCMA #BsAbTherapy #Teclistamab #ClinicalResearch #ClinicalInsights #HematologyEducation #HEMEHUB
Resistance and Biomarkers
#Hematology #MultipleMyeloma #MedEd #Immunotherapy #BCMA #BsAbTherapy #Teclistamab #ClinicalResearch #ClinicalInsights #HematologyEducation #HEMEHUB
February 19, 2026 at 2:45 AM
🩸Facts about Multiple Myeloma:
Resistance and Biomarkers
#Hematology #MultipleMyeloma #MedEd #Immunotherapy #BCMA #BsAbTherapy #Teclistamab #ClinicalResearch #ClinicalInsights #HematologyEducation #HEMEHUB
Resistance and Biomarkers
#Hematology #MultipleMyeloma #MedEd #Immunotherapy #BCMA #BsAbTherapy #Teclistamab #ClinicalResearch #ClinicalInsights #HematologyEducation #HEMEHUB
🩸 Advancing hematology education together!
Committed to sharing expertise and fostering knowledge through collaboration and learning.
🌐 Explore more: hemehub.org
#Hematology #MedEd #ClinicalEducation #HemeHub #ClinicalLearning #Partnerships #TexasOncology #UPA #WhitetulipHealthFoundation
Committed to sharing expertise and fostering knowledge through collaboration and learning.
🌐 Explore more: hemehub.org
#Hematology #MedEd #ClinicalEducation #HemeHub #ClinicalLearning #Partnerships #TexasOncology #UPA #WhitetulipHealthFoundation
🩸We are proud to partner with Texas Oncology, Whitetulip Health Foundation, and United Porphyrias Association to advance hematology education through collaboration and shared expertise.
🌐 Explore more: hemehub.org
#Hematology #MedEd #HemeHub #ClinicalLearning #Partnerships
🌐 Explore more: hemehub.org
#Hematology #MedEd #HemeHub #ClinicalLearning #Partnerships
February 19, 2026 at 2:44 AM
🩸 Advancing hematology education together!
Committed to sharing expertise and fostering knowledge through collaboration and learning.
🌐 Explore more: hemehub.org
#Hematology #MedEd #ClinicalEducation #HemeHub #ClinicalLearning #Partnerships #TexasOncology #UPA #WhitetulipHealthFoundation
Committed to sharing expertise and fostering knowledge through collaboration and learning.
🌐 Explore more: hemehub.org
#Hematology #MedEd #ClinicalEducation #HemeHub #ClinicalLearning #Partnerships #TexasOncology #UPA #WhitetulipHealthFoundation
Explore the February #ExpHem issue, with articles from the labs of Jean-Pierre Lévesque, @ganuzalab.bsky.social, Katrin Ottersbach, Duonan Yu and more! Read the latest research in experimental hematology now on www.exphem.org.
February 18, 2026 at 9:01 PM
Explore the February #ExpHem issue, with articles from the labs of Jean-Pierre Lévesque, @ganuzalab.bsky.social, Katrin Ottersbach, Duonan Yu and more! Read the latest research in experimental hematology now on www.exphem.org.
Dr. Negrin shares in The Hematologist his outlook for the year ahead as ASH President, highlighting progress in hematology while emphasizing community, advocacy, and mentorship. Read the full article now: ashpublications.org/...
#HemeSky #MedSky
#HemeSky #MedSky
February 18, 2026 at 8:00 PM
Dr. Negrin shares in The Hematologist his outlook for the year ahead as ASH President, highlighting progress in hematology while emphasizing community, advocacy, and mentorship. Read the full article now: ashpublications.org/...
#HemeSky #MedSky
#HemeSky #MedSky
My suggestion won💚👽
The analyzer on the left can do one extra test the one on the right can't do, so naturally it was named Scully 😊🧪🩸
The analyzer on the left can do one extra test the one on the right can't do, so naturally it was named Scully 😊🧪🩸
February 18, 2026 at 6:37 PM
My suggestion won💚👽
The analyzer on the left can do one extra test the one on the right can't do, so naturally it was named Scully 😊🧪🩸
The analyzer on the left can do one extra test the one on the right can't do, so naturally it was named Scully 😊🧪🩸
Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer 2026, Boise: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky
February 18, 2026 at 6:10 PM
Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer 2026, Boise: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky
Emicizumab reduced mean ABR from 11.48 to 0.05 over 12 months.
71% of patients remained bleed-free compared to 35% at baseline.
Target joint bleeding decreased by 82% during the study period.
Read the review: https://bit.ly/4c2doPQ
#Hematology #HemophiliaA #ClinicalData #PrecisionMedicine
71% of patients remained bleed-free compared to 35% at baseline.
Target joint bleeding decreased by 82% during the study period.
Read the review: https://bit.ly/4c2doPQ
#Hematology #HemophiliaA #ClinicalData #PrecisionMedicine
Emicizumab Prophylaxis May Be Safe, Effective in Infants With Hemophilia A
Emicizumab prophylaxis was considered potentially safe and effective in a real-world, international study of infants with hemophilia A.
bit.ly
February 18, 2026 at 6:09 PM
Emicizumab reduced mean ABR from 11.48 to 0.05 over 12 months.
71% of patients remained bleed-free compared to 35% at baseline.
Target joint bleeding decreased by 82% during the study period.
Read the review: https://bit.ly/4c2doPQ
#Hematology #HemophiliaA #ClinicalData #PrecisionMedicine
71% of patients remained bleed-free compared to 35% at baseline.
Target joint bleeding decreased by 82% during the study period.
Read the review: https://bit.ly/4c2doPQ
#Hematology #HemophiliaA #ClinicalData #PrecisionMedicine
WVU Cancer Institute First in the World to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy @wvumedschool.bsky.social #leusm #hematology #oncology
www.onclive.com/view/wvu-can...
www.onclive.com/view/wvu-can...
WVU Cancer Institute First in the World to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy | OncLive
A WVU Cancer Institute team investigated the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.
www.onclive.com
February 18, 2026 at 5:16 PM
WVU Cancer Institute First in the World to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy @wvumedschool.bsky.social #leusm #hematology #oncology
www.onclive.com/view/wvu-can...
www.onclive.com/view/wvu-can...
A comprehensive mapping of hematopoiesis, demonstrating the transition from self-renewing Pluripotent Hematopoietic Stem Cells (HSCs) to specialized effector cells.
Professional Hashtags:
#MolecularBiology #Immunology #Hematology #Genetics #CellBiology #StructuralBiology #STEM
Professional Hashtags:
#MolecularBiology #Immunology #Hematology #Genetics #CellBiology #StructuralBiology #STEM
February 18, 2026 at 5:01 PM
A comprehensive mapping of hematopoiesis, demonstrating the transition from self-renewing Pluripotent Hematopoietic Stem Cells (HSCs) to specialized effector cells.
Professional Hashtags:
#MolecularBiology #Immunology #Hematology #Genetics #CellBiology #StructuralBiology #STEM
Professional Hashtags:
#MolecularBiology #Immunology #Hematology #Genetics #CellBiology #StructuralBiology #STEM
Job ID: 108199
Extract: The Division of Hematology seeks a Data Analyst to prioritize and extract data from various sources, design reports, and ensure data accuracy. The role involves statistical analyses and collaboration with internal and external partners.
Extract: The Division of Hematology seeks a Data Analyst to prioritize and extract data from various sources, design reports, and ensure data accuracy. The role involves statistical analyses and collaboration with internal and external partners.
February 18, 2026 at 5:01 PM
Job ID: 108199
Extract: The Division of Hematology seeks a Data Analyst to prioritize and extract data from various sources, design reports, and ensure data accuracy. The role involves statistical analyses and collaboration with internal and external partners.
Extract: The Division of Hematology seeks a Data Analyst to prioritize and extract data from various sources, design reports, and ensure data accuracy. The role involves statistical analyses and collaboration with internal and external partners.
Stanford University is hiring:
Cancer Clinical Research Coordinator Associate - Hematology
#otherposition
Cancer Clinical Research Coordinator Associate - Hematology
#otherposition
February 18, 2026 at 4:16 PM
Stanford University is hiring:
Cancer Clinical Research Coordinator Associate - Hematology
#otherposition
Cancer Clinical Research Coordinator Associate - Hematology
#otherposition
Laut einer in der Zeitschrift Blood Red Cells & Iron der American Society of Hematology veröffentlichten Studie schädigt extremes Ausdauerlaufen die roten Blutkörperchen auf eine Weise, die ihre Funktionsfähigkeit beeinträchtigen kann.
https://www.bytesde.com/1728148/
Laut einer in der …
https://www.bytesde.com/1728148/
Laut einer in der …
Laut einer in der Zeitschrift Blood Red Cells & Iron der American Society of Hematology veröffentlichten Studie schädigt extremes Ausdauerlaufen die roten Blutkörperchen auf eine Weise, die ihre Funktionsfähigkeit beeinträchtigen kann. - Bytes Deutschland
Laut einer in der Zeitschrift Blood Red Cells & Iron der American Society of Hematology veröffentlichten Studie schädigt extremes Ausdauerlaufen die roten
www.bytesde.com
February 18, 2026 at 4:00 PM
Laut einer in der Zeitschrift Blood Red Cells & Iron der American Society of Hematology veröffentlichten Studie schädigt extremes Ausdauerlaufen die roten Blutkörperchen auf eine Weise, die ihre Funktionsfähigkeit beeinträchtigen kann.
https://www.bytesde.com/1728148/
Laut einer in der …
https://www.bytesde.com/1728148/
Laut einer in der …
Can extreme endurance running change how red blood cells function? 🏃♀️🩸
New research published in Blood Red Cells & Iron suggests that ultra endurance races may damage red blood cells and reduce their flexibility.
Learn more in the press release: https://bit.ly/4ao3F59
#Hematology
New research published in Blood Red Cells & Iron suggests that ultra endurance races may damage red blood cells and reduce their flexibility.
Learn more in the press release: https://bit.ly/4ao3F59
#Hematology
February 18, 2026 at 3:45 PM
Can extreme endurance running change how red blood cells function? 🏃♀️🩸
New research published in Blood Red Cells & Iron suggests that ultra endurance races may damage red blood cells and reduce their flexibility.
Learn more in the press release: https://bit.ly/4ao3F59
#Hematology
New research published in Blood Red Cells & Iron suggests that ultra endurance races may damage red blood cells and reduce their flexibility.
Learn more in the press release: https://bit.ly/4ao3F59
#Hematology
Coming soon! ASH is collaborating with the @US_FDA for an exclusive workshop on regulatory science in #hematology.
Applications will open on March 10, 2026. Stay tuned!
Applications will open on March 10, 2026. Stay tuned!
February 18, 2026 at 1:00 PM
Coming soon! ASH is collaborating with the @US_FDA for an exclusive workshop on regulatory science in #hematology.
Applications will open on March 10, 2026. Stay tuned!
Applications will open on March 10, 2026. Stay tuned!
🔷 If approved, iberdomide could offer a novel treatment option for heavily pretreated patients with limited therapeutic choices.
🔗 Read more: bit.ly/ONCOnews18Fe...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #CancerTreatment #FDA #FDAApproval
🔗 Read more: bit.ly/ONCOnews18Fe...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #CancerTreatment #FDA #FDAApproval
ONCOassist Universal Link
Opening ONCOassist app...
bit.ly
February 18, 2026 at 10:30 AM
🔷 If approved, iberdomide could offer a novel treatment option for heavily pretreated patients with limited therapeutic choices.
🔗 Read more: bit.ly/ONCOnews18Fe...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #CancerTreatment #FDA #FDAApproval
🔗 Read more: bit.ly/ONCOnews18Fe...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #CancerTreatment #FDA #FDAApproval
Wonderful visit to UW–Madison (@uwmadison.bsky.social) for a seminar! Thank you, Owen (@otamplin.bsky.social), for the kind invitation. Great catching up with an incredible group of hematology/stem cell researchers, including Emery, Xin Gao, and Marjorie. Excited to explore collaborations!
February 18, 2026 at 10:13 AM
Wonderful visit to UW–Madison (@uwmadison.bsky.social) for a seminar! Thank you, Owen (@otamplin.bsky.social), for the kind invitation. Great catching up with an incredible group of hematology/stem cell researchers, including Emery, Xin Gao, and Marjorie. Excited to explore collaborations!
Hematology Diagnostics Companies | Market Research Future www.marketresearchfuture.com/reports/hema...
Hematology Diagnostics Companies | Market Research Future
www.marketresearchfuture.com
February 18, 2026 at 7:01 AM
Hematology Diagnostics Companies | Market Research Future www.marketresearchfuture.com/reports/hema...
Who are the Black pioneers in hematology whose contributions inspire you? Share their names and stories in the comments.
February 18, 2026 at 1:58 AM
Who are the Black pioneers in hematology whose contributions inspire you? Share their names and stories in the comments.
This #BlackHistoryMonth, ASH honors the Black pioneers in #hematology whose discoveries, leadership, and advocacy have shaped the field and continue to save lives. Their impact lives on in every breakthrough and every patient served.
February 18, 2026 at 1:58 AM
This #BlackHistoryMonth, ASH honors the Black pioneers in #hematology whose discoveries, leadership, and advocacy have shaped the field and continue to save lives. Their impact lives on in every breakthrough and every patient served.
For the 6th year in a row, Cedars-Sinai’s Division of Hematology and Cellular Therapy achieved higher than expected survival rates in allogeneic stem cell transplant patients based on data from the Center for International Blood and Marrow Transplant Research!
www.cedars-sinai.org/newsroom/ced...
www.cedars-sinai.org/newsroom/ced...
Cedars-Sinai Earns Top Stem Cell Transplant Ranking
Cedars-Sinai earns top ranking for stem cell transplant patient outcomes for the sixth time from Center for International Bone and Marrow Transplant Research.
www.cedars-sinai.org
February 17, 2026 at 10:59 PM
For the 6th year in a row, Cedars-Sinai’s Division of Hematology and Cellular Therapy achieved higher than expected survival rates in allogeneic stem cell transplant patients based on data from the Center for International Blood and Marrow Transplant Research!
www.cedars-sinai.org/newsroom/ced...
www.cedars-sinai.org/newsroom/ced...
Clonal hematopoiesis associated with 20.3% 10-year HF risk vs 14.5% in non-carriers.
- Ischemic CVD risk: 25.3% vs 18.5%.
- Risk amplified in patients receiving ≥7 chemotherapy cycles.
With @jamacardiology.com. Read more: ➡️ https://bit.ly/46XA7cm
#Hematology #CardioOncology #CHIP #HeartFailure
- Ischemic CVD risk: 25.3% vs 18.5%.
- Risk amplified in patients receiving ≥7 chemotherapy cycles.
With @jamacardiology.com. Read more: ➡️ https://bit.ly/46XA7cm
#Hematology #CardioOncology #CHIP #HeartFailure
CHIP Significantly Associated With Heart Failure
Researchers determined CHIP is associated with incident heart failure.
bit.ly
February 17, 2026 at 8:15 PM
Clonal hematopoiesis associated with 20.3% 10-year HF risk vs 14.5% in non-carriers.
- Ischemic CVD risk: 25.3% vs 18.5%.
- Risk amplified in patients receiving ≥7 chemotherapy cycles.
With @jamacardiology.com. Read more: ➡️ https://bit.ly/46XA7cm
#Hematology #CardioOncology #CHIP #HeartFailure
- Ischemic CVD risk: 25.3% vs 18.5%.
- Risk amplified in patients receiving ≥7 chemotherapy cycles.
With @jamacardiology.com. Read more: ➡️ https://bit.ly/46XA7cm
#Hematology #CardioOncology #CHIP #HeartFailure